News - Pradaxa, Elan

Filter

Current filters:

PradaxaElan

Popular Filters

1 to 25 of 72 results

Boehringer analysis finds better outcome for Pradaxa compared to warfarin

Boehringer analysis finds better outcome for Pradaxa compared to warfarin

08-10-2013

Boehringer Ingelheim has released new data showing better survival prognosis following a major bleeding…

Boehringer IngelheimHematologyPharmaceuticalPradaxaResearch

Boehringer Ingelheim plans to expand body of evidence for Pradaxa

04-09-2013

German family-owned drug major Boehringer Ingelheim has announced new milestones for the novel oral anticoagulant…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

Pradaxa sNDA for DVT and PE accepted by FDA

28-08-2013

The US Food and Drug Administration has accepted for review German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Elan board agrees $8.6 billion takeover bid

29-07-2013

US health care company Perrigo (NYSE: PRGO) revealed this morning that Ireland-based drugmaker Elan Corp…

ElanGenericsMergers & AcquisitionsPerrigoPharmaceuticalTysabri

Elan posts financials, as it explores sale of the company

25-07-2013

Ireland-based Elan Corp (NYSE:ELN) today reported its second quarter 2013 financial results, showing…

ElanFinancialMergers & AcquisitionsPharmaceuticalTysabri

US FDA fast-tracks Elan's Alzheimer's drug candidate

18-07-2013

Ireland-based Elan Corp (NYSE: ELN) says that the US Food and Drug Administration has granted Fast Track…

ElanELND005GlobalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulation

Royalty pulls plug on Elan buy (for now?); analysts' view on what comes next

19-06-2013

In the ongoing hostile takeover saga, US private equity firm Royalty Pharma has withdrawn its request…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

AOP Orphan spins off stake in Activartis as Elan shareholders vote down acquisition

18-06-2013

In the wake of yesterday's shareholders vote against Irish drugmaker Elan Corp's (NYSE: ELN) planned…

ActivartisAOP OrphanElanMergers & AcquisitionsOncologyPharmaceutical

Royalty Pharma hostile bid lapses as Elan shareholders vote for share repurchase but not Theravance, AOP or ELND005 deals

17-06-2013

At the company's Extraordinary General Meeting held earlier today (June 17), shareholders of Ireland-based…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan puts up formal "for sale" notice

17-06-2013

Ireland-based Elan Corp (NYSE:ELN), which has been the subject of a hostile takeover campaign by private…

Biogen IdecElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty bid for Elan could be withdrawn; J&J sells 25.4 million Elan shares

14-06-2013

Ireland-based hostile takeover target Elan (NYSE: ELN) fell 5.2% to 9.29 euros on June 13, the most in…

ElanJohnson & JohnsonMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan board unreservedly rejects Royalty's increased tender offer

11-06-2013

Ireland-based drugmaker Elan Corp (NYSE: ELN) says that its board of directors, after careful review…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty Pharma hikes offer for Elan to $13 a share, plus CVR of up to $2.50

10-06-2013

Ireland-based Elan Corp (NYSE: ELN) saw its shares to 5.3% to $13.35 by mid morning last Friday (June…

ElanMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan details further inadequacy of Royalty Pharma's revised offer; takes legal action

04-06-2013

The saga of Royalty Pharma's hostile attempts to acquire Ireland-headquartered Elan Corp (NYSE: ELN)…

ElanLegalMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan tells shareholders it is worth up to $20.80 a share and they should not accept Royalty's $12.50 offer

30-05-2013

In the ongoing saga of Royalty Pharma's takeover attempts, Ireland-based Elan (NYSE: ELN) has communicated…

ElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan rejects Royalty Pharma's increased bid; prices Senior Notes offering

24-05-2013

Ireland-based takeover target Elan Corp (NYSE: ELN) says that its board of directors, after careful review…

ElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty Pharma ups bid for Elan to $12.50 a share

21-05-2013

ot on the heels of Ireland-based drugmaker Elan Corp's (NYSE: ELN) own acquisition plans (it is to buy…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan makes "transformational" acquisitions and a divestment

20-05-2013

Ireland-headquartered Elan Corp (NYSE: ELN) (Elan) this morning announced a series of transactions designed…

AOP OrphanElanELND005Mergers & AcquisitionsNewBridge PharmaceuticalsPharmaceuticalSperanza Therapeutics

Elan reports 1st-qtr operating loss

24-04-2013

Ireland-based Elan Corp (NYSE: ELN), which has again rejected takeover approach form Royalty Pharma and…

ElanFinancialPharmaceuticalTysabri

1 to 25 of 72 results

Back to top